Literature DB >> 20053466

Opposing cardiac effects of autoantibody activation of β-adrenergic and M2 muscarinic receptors in cardiac-related diseases.

Stavros Stavrakis1, David C Kem, Eugene Patterson, Pedro Lozano, Shijun Huang, Bela Szabo, Madeleine W Cunningham, Ralph Lazzara, Xichun Yu.   

Abstract

BACKGROUND: Activating autoantibodies to β-adrenergic receptors (AAβ1/2AR) and M2 muscarinic receptors (AAM2R) have been reported in several cardiac diseases and may have pathophysiologic relevance. However, the interactions and relative effects of AAβ1AR, AAβ2AR and AAM2R on contractile function have not been characterized.
METHODS: The inotropic effects of IgG from 18 selected patients with cardiomyopathy and/or atrial tachyarrhythmias positive by ELISA for antibodies to β1/2AR were studied using an isolated canine Purkinje fiber contractility assay. M2R-blockade was tested using atropine while selective β1AR and β2AR blockade used CGP-20712A and ICI-118551 respectively.
RESULTS: Fifteen of the 18 anti-β1/2AR ELISA-positive samples demonstrated evidence for negative inotropic muscarinic effects which were blocked using atropine. Atropine failed to uncover a positive inotropic response in 2 of the 18 IgG samples (false positive ELISA for AAβAR). In the remaining 16 AAβAR true-positive subjects, the β1AR-induced increase in contractility (concurrent M2/β2 blockade) was augmented to 140.5±12.2% of baseline compared to 127.4±7.2% of baseline with M2 blockade (atropine) only (p<0.001, n=16). The β2AR-induced increase in contractility (concurrent M2/β1 blockade) was only 114.5±4.3% of baseline (p<0.001, n=16). Combined M2 and β1/β2 blockade eliminated any increase in contractility.
CONCLUSIONS: The inherently positive inotropic effect of AAβ1AR was negatively modulated by AAM2R and AAβ2AR. These opposing effects of receptor-activating autoantibodies may alter cardiac performance and influence clinical outcome depending on their receptor type and relative contractile activity.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053466      PMCID: PMC3108570          DOI: 10.1016/j.ijcard.2009.11.025

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  34 in total

1.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.

Authors:  C Communal; K Singh; D B Sawyer; W S Colucci
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

Review 2.  Muscarinic receptors in the mammalian heart.

Authors:  S Dhein; C J van Koppen; O E Brodde
Journal:  Pharmacol Res       Date:  2001-09       Impact factor: 7.658

3.  Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes.

Authors:  T Christ; E Wettwer; D Dobrev; E Adolph; M Knaut; G Wallukat; U Ravens
Journal:  J Mol Cell Cardiol       Date:  2001-08       Impact factor: 5.000

Review 4.  Muscarinic regulation of cardiac ion channels.

Authors:  Robert D Harvey; Andriy E Belevych
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Ethical authorship and publishing.

Authors:  Andrew J S Coats
Journal:  Int J Cardiol       Date:  2008-11-28       Impact factor: 4.164

6.  Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction.

Authors:  P A Chiale; I Ferrari; E Mahler; M A Vallazza; M V Elizari; M B Rosenbaum; M J Levin
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.

Authors:  Roland Jahns; Valérie Boivin; Lutz Hein; Sven Triebel; Christiane E Angermann; Georg Ertl; Martin J Lohse
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy.

Authors:  Akiyasu Baba; Tsutomu Yoshikawa; Yukiko Fukuda; Takashi Sugiyama; Megumi Shimada; Makoto Akaishi; Kanji Tsuchimoto; Satoshi Ogawa; Michael Fu
Journal:  Eur Heart J       Date:  2004-07       Impact factor: 29.983

9.  Autoantibodies against the myocardial beta1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure.

Authors:  Lin Zhang; Dayi Hu; Jing Li; Yafeng Wu; Xiulan Liu; Xinchun Yang
Journal:  Chin Med J (Engl)       Date:  2002-08       Impact factor: 2.628

Review 10.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

View more
  14 in total

Review 1.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

2.  Decrease in heart adrenoceptor gene expression and receptor number as compensatory tool for preserved heart function and biological rhythm in M(2) KO animals.

Authors:  Jan Benes; Eva Varejkova; Vladimir Farar; Martina Novakova; Jaromir Myslivecek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-24       Impact factor: 3.000

3.  Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism.

Authors:  Hongliang Li; David C Kem; Sean Reim; Muneer Khan; Megan Vanderlinde-Wood; Caitlin Zillner; Daniel Collier; Campbell Liles; Michael A Hill; Madeleine W Cunningham; Christopher E Aston; Xichun Yu
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

Review 4.  The Role of B Cells in Cardiomyopathy and Heart Failure.

Authors:  Kevin Bermea; Aashik Bhalodia; Angelo Huff; Sylvie Rousseau; Luigi Adamo
Journal:  Curr Cardiol Rep       Date:  2022-06-11       Impact factor: 3.955

5.  Targeting individual GPCRs with redesigned nonvisual arrestins.

Authors:  Luis E Gimenez; Sergey A Vishnivetskiy; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

6.  Antibodies to cardiac receptors.

Authors:  V Boivin-Jahns; A Schlipp; S Hartmann; P Panjwani; K Klingel; M J Lohse; G Ertl; R Jahns
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

Review 7.  Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function.

Authors:  L R Herda; S B Felix; F Boege
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

8.  Mitochondrial Ultrastructural Alterations and Declined M2 Receptor Density Were Involved in Cardiac Dysfunction in Rats after Long Term Treatment with Autoantibodies against M2 Muscarinic Receptor.

Authors:  Suli Zhang; Zhongmei He; Jin Wang; Li Wang; Ye Wu; Jie Wang; Tingting Lv; Huirong Liu
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

9.  Impact of human autoantibodies on β1-adrenergic receptor conformation, activity, and internalization.

Authors:  Beatrice Bornholz; Stefanie Weidtkamp-Peters; Stephanie Schmitmeier; Claus A M Seidel; Lars R Herda; Stephan B Felix; Horst Lemoine; Jürgen Hescheler; Filomain Nguemo; Christoph Schäfer; Morten O Christensen; Christian Mielke; Fritz Boege
Journal:  Cardiovasc Res       Date:  2012-12-03       Impact factor: 10.787

Review 10.  Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management.

Authors:  Alida L P Caforio; Renzo Marcolongo; Roland Jahns; Michael Fu; Stephan B Felix; S Iliceto
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.